The influence of dapagliflozin on cardiac remodeling, myocardial function and metabolomics in type 1 diabetes mellitus rats
Sodium-glucose cotransporter (SGLT)2 inhibitors have displayed beneficial effects on the cardiovascular system in diabetes mellitus (DM) patients. As most clinical trials were performed in Type 2 DM, their eff...
Source: Diabetology and Metabolic Syndrome - Category: Endocrinology Authors: Eder Anderson Rodrigues, Camila Moreno Rosa, Dijon Henrique Salome Campos, Felipe Cesar Damatto, Gilson Masahiro Murata, Lidiane Moreira Souza, Luana Urbano Pagan, Mariana Gatto, Jessica Yumi Brosler, Hebreia Oliveira Almeida Souza, Mario Machado Martins, Tags: Research Source Type: research
More News: Cardiology | Cardiovascular | Clinical Trials | Dapagliflozin | Diabetes | Diabetes Mellitus | Diabetes Type 1 | Diabetes Type 2 | Endocrinology | Forxiga | Heart | Metabolic Syndrome | Sodium